Galectin Therapeutics Inc (NASDAQ: GALT) on Friday, soared 8.07% from the previous trading day, before settling in for the closing price of $3.84. Within the past 52 weeks, GALT’s price has moved between $0.73 and $3.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -23.89%. The company achieved an average annual earnings per share of 11.84%. With a float of $43.41 million, this company’s outstanding shares have now reached $63.29 million.
The extent of productivity of a business whose workforce counts for 15 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Galectin Therapeutics Inc (GALT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Galectin Therapeutics Inc is 31.41%, while institutional ownership is 14.81%. The most recent insider transaction that took place on Jul 21 ’25, was worth 2,925. In this transaction Director of this company bought 1,000 shares at a rate of $2.92, taking the stock ownership to the 64,682 shares. Before that another transaction happened on Jul 17 ’25, when Company’s Director bought 5,000 for $2.90, making the entire transaction worth $14,495. This insider now owns 49,769 shares in total.
Galectin Therapeutics Inc (GALT) Performance Highlights and Predictions
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.2 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.16) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.84% per share during the next fiscal year.
Galectin Therapeutics Inc (NASDAQ: GALT) Trading Performance Indicators
Galectin Therapeutics Inc (GALT) is currently performing well based on its current performance indicators. A quick ratio of 0.08 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.72, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of Galectin Therapeutics Inc (GALT)
The latest stats from [Galectin Therapeutics Inc, GALT] show that its last 5-days average volume of 0.32 million was inferior to 0.42 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 88.59%.
During the past 100 days, Galectin Therapeutics Inc’s (GALT) raw stochastic average was set at 92.10%, which indicates a significant increase from 86.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.45, while its 200-day Moving Average is $1.88.
